It’s all semantics for the sake of staying within guidelines and corporate strategy. Data has been shared that can be considered “top line data” but since this sharing came from the clinical trial community and does not speak for the company, an official form of a legally binding top line data statement from the company has not occurred nor has a more in depth explanation and commentary on other known endpoints been given yet. These will come at a coordinated time per NWBO statements. Best wishes.